LIU Qiaoqiong,TU Jianxin,LIN Xiaoyun, et al. Prokaryotic expression and immunogenicity of major outer membrane protein 21-387 from Chlamydia trachomatis[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2015, 45(2): 95-.
Abstract：Objective: To explore prokaryotic expression and immunogenicity of major outer membrane protein (MOMP21-387) of Chlamydia trachomatis serotype E. Methods: The gene encoding MOMP21-387 was amplified from genome DNA of C. trachomatis E by PCR analysis, and then cloned into pET21a (+) vector to construct recombinant plasmid pET21a (+)/MOMP21-387, and was expressed in the prokaryotic expression system. The MOMP21-387 fusion protein was purified and identified by SDS-PAGE and western blot analysis. The immunogenicity was further assessed by immunizing BABL/c mice, the reactivity of specific serum IgG in serum and genital tract mucosal IgA were tested by ELISA, and the specific cytotoxicity of spleen cells was detected with lactate dehydrogenase (LDH) method. Results: The MOMP21-387 fusion protein was successfully expressed in a prokaryotic expression system, and the specific positive bands at the relative molecular mass (Mr) of about 44 000 was confirmed by SDS-PAGE and western blot analysis; And the purified MOMP21-387 fusion protein was obtained with the Ni-NTA affinity chromatography method. The mice can be induced to produce the specific serum IgG and reproductive tract mucosal IgA by immunizing with the MOMP21-387 fusion protein, and the value of the specific serum IgG and mucosal IgAin immunized groups were significantly higher than that of the PBS control group (P<0.05), the antibodys detected by ELISA reached peak at the 6th week post-immunization. The LDH analysis showed that, the killing rate of spleen cells to the target cell in MOMP21-387 protein immunized groups was significantly higher than those in PBS control group, when the effector cells to target ratio reached to 10:1, 20:1, 40:1 and 80:1 (P<0.05). Conclusion: The MOMP21-387 fusion protein of Chlamydia trachomatis serovar E shows good immunogenicity, It may lay the foundation for the Chlamydia trachomatis ELISA detection and vaccine development based on MOMP21-387.
[1]Hu VH, Holland MJ, Burton MJ, et al. Trachoma: protective and pathogenic ocular immune responses to Chlamydia trachomatis[J]. PLoS Negl Trop Dis, 2013, 7(2): 1-13.
[2]Han Y, Yin YP, Shi MQ, et al. Difference in distribution of Chlamydia trachomatis genotypes among different provinces: a pilot study from four provinces in China[J]. Jpn J Infect Dis, 2013, 66(1): 69-71.
[3]Donati M, Di Francesco A, D’Antuono A, et al. Chlamyia trachomatis serovar distribution and other concurrent sexually transmitted infections in heterosexual men with urethritis in Italy[J]. Eur J Clin Microbiol Infect Dis, 2009, 28(5): 523-526.
[4]Choroszy-Krol IC, Frej-Madrzak M, Jama-Kmiecik A, et al. Characteristics of the Chlamydia trachomatis species-immunopathology and infections[J]. Adv Clin Exp Med,2012, 21(6): 799-808.
[5]幺山山, 曾明. 沙眼衣原体疫苗的研发[J]. 国际生物制品学杂志, 2013, 36(1): 17-21.
[6]Ercolini AM, Miller SD. The role of infections in autoimmune disease[J]. Clin Exp Immunol, 2009, 155(1): 1-15.
[7]Findlay HE, McClafferty H, Ashley RH, et al. Surface expression, single-channel analysis and membrane topology of recombinant Chlamydia trachomatis Major Outer Mem-brane Protein[J]. BMC Microbiology, 2005, 5(1): 1-15.
[8]Zhu S, Chen J, Zheng M, et al. Identification of immuno-dominant linear B-cell epitopes within the major outer membrane protein of Chlamydia trachomatis[J]. Acta Biochim Biophys Sin, 2010, 42(11): 771-778.
[9]Wallner M, Gruber P, Radauer C, et al. Lab scale and medium scale production of recombinant allergens in Esche-richia coli[J]. METHODS, 2004, 32(3): 219-226.
[10]Cheng C, Pal S, Tifrea D, et al. A vaccine formulated with a combination of TLR-2 and TLR-9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response and significant protection against a Chla-mydia muridarum challenge[J]. Microbes Infect, 2014, 16(3): 244-252.
[11]Pal S, Theodor I, Peterson EM, et al. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge[J]. Infect Immunity, 2001, 69 (10): 6240-6247.
[12]Stephens RS, Mullenbach G, Sanchez-Pescador R, et al. Sequence analysis of the major outer membrane protein gene from Chlamydia trachomatis serovar L2[J]. JB, 1986, 168 (3): 1277-1282.
[13]Jones HM, Kubo A, Stephens RS. Design, expression and functional characterization of a synthetic gene encoding the Chlamydia trachomatis major outer membrane protein[J].Gene, 2000, 258(1): 173-181.
[14]Tobias JW, Shrader TE, Rocap G, et al. The N-end rule inbacteria[J]. Science, 1991, 254(5036): 1374-1377.
[15]Ucisik MN, Chakravorty DK, Merz KM Jr. Structure and dynamics of the N-terminal domain of the Cu(I) binding protein CusB[J]. Biochemistry, 2013, 52(39): 6911-6923.
[16]Hirel PH, Schmitter MJ, Dessen P, et al. Extent of N-terminal methionine excision from Escherichia coli proteins is governed by the side-chain length of the penultimate amino acid[J]. Proc Natl Acad Sci USA, 1989, 86(21): 8247-8251.
[17]Arsovic A, Nikolov A, Sazdanovic P, et al. Prevalence and diagnostic significance of specific IgA and anti-heat shock protein 60 Chlamydia trachomatis antibodies in subfertile women[J]. Eur J Clin Microbiol Infect Dis, 2014, 33(5):761-766.
[18]Brunham RC, Rey-Ladino J. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine [J]. Nat Rev Immunol, 2005, 5(2): 149-161.
[19]Joyee AG, Yang X. Plasmacytoid dendritic cells mediate the regulation of inflammatory type T cell response for optimal immunity against respiratory Chlamydia pneumoniae infection[J]. PLoS ONE, 2013, 8(12): 1-13.
[20]吕慧, 赵蔚明, 于修平, 等. E型沙眼衣原体MOMP基因重组腺病毒的构建及免疫原性研究[J]. 山东大学学报(医学版), 2006, 44(12): 1189-1193.
